Meng Yifan, Cui Lanyue, Fang Cheng, Yang Fan, Li Jundong, Wan Ting
Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Int J Surg. 2025 Sep 1;111(9):6211-6220. doi: 10.1097/JS9.0000000000002731. Epub 2025 Jun 13.
The prognostic equivalence of total hysterectomy (TH) versus radical hysterectomy (RH) in early-stage cervical cancer (IA2-IB1) with tumor size ≤2 cm remains controversial, particularly regarding the necessity of lymphovascular space invasion (LVSI) assessment. This study evaluates survival outcomes under simplified criteria omitting LVSI and depth of invasion evaluation.
This retrospective cohort study analyzed 3002 FIGO IA2-IB1 cervical cancer patients (tumors ≤2 cm) from the SEER database (2004-2019). Inclusion criteria are histologically confirmed adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma; TH/RH with lymphadenectomy/sentinel node biopsy. Outcomes included overall survival (OS) and disease-specific survival (DSS), analyzed via Kaplan-Meier, Cox regression, and propensity score matching (PSM).
Median follow-up was 73 months. No significant differences were observed in OS (92.3% vs. 92.3%, P = 0.74) and DSS (96.4% vs. 96.6%, P = 0.89) outcomes between RH and TH cohorts, consistent across FIGO stages and adjuvant therapy-without patients. Multivariable analysis confirmed age >49 years (HR = 2.50, 95% CI = 1.91-3.28, P < 0.01), marital status of separated/divorced/widowed (HR = 1.66, 95% CI = 1.20-2.28, P < 0.01), and tumor size 11-20 mm (HR = 1.61, 95% CI = 1.18-2.19, P < 0.01) as independent risk factors in OS. While surgical approach still showed no prognostic significance both in OS (HR = 1.04, 95% CI = 0.79-1.37, P = 0.77) and DSS (HR = 1.01, 95% CI = 0.67-1.53, P = 0.96). Post-PSM analysis ( n = 2,715) confirmed survival equivalence ( P > 0.05). However, in IB1 adenosquamous/adenocarcinoma patients aged >49 years with tumors 11-20 mm, RH achieved superior DSS ( P = 0.01), though OS differences were nonsignificant ( P = 0.085). Squamous carcinoma outcomes remained equivalent regardless of surgery ( P = 0.43).
TH achieves survival outcomes comparable to RH in most early-stage cervical cancer patients with tumors ≤2 cm, supporting its application in low-risk populations. However, RH remains preferred for stage IB1 patients with adenocarcinoma or adenosquamous carcinoma aged >49 years and tumors measuring 11-20 mm. Simplified criteria omitting LVSI and stromal depth assessment may enhance accessibility in resource-limited settings without compromising safety.
对于肿瘤大小≤2cm的早期宫颈癌(IA2 - IB1期)患者,全子宫切除术(TH)与根治性子宫切除术(RH)的预后等效性仍存在争议,尤其是在淋巴血管间隙浸润(LVSI)评估的必要性方面。本研究评估了省略LVSI和浸润深度评估的简化标准下的生存结果。
这项回顾性队列研究分析了SEER数据库(2004 - 2019年)中3002例FIGO IA2 - IB1期宫颈癌患者(肿瘤≤2cm)。纳入标准为组织学确诊的腺癌、腺鳞癌或鳞状细胞癌;接受TH/RH并进行淋巴结清扫/前哨淋巴结活检。观察指标包括总生存期(OS)和疾病特异性生存期(DSS),通过Kaplan - Meier法、Cox回归和倾向评分匹配(PSM)进行分析。
中位随访时间为73个月。RH组和TH组在OS(92.3%对92.3%,P = 0.74)和DSS(96.4%对96.6%,P = 0.89)结果上未观察到显著差异,在FIGO各分期和辅助治疗患者中均一致。多变量分析确认年龄>49岁(HR = 2.50,95%CI = 1.91 - 3.28,P < 0.01)、分居/离婚/丧偶婚姻状况(HR = 1.66,95%CI = 1.20 - 2.28,P < 0.01)以及肿瘤大小11 - 20mm(HR = 1.61,95%CI = 1.18 - 2.19,P < 0.01)是OS的独立危险因素。而手术方式在OS(HR = 1.04,95%CI = 0.79 - 1.37,P = 0.77)和DSS(HR = 1.01,95%CI = 0.67 - 1.53,P = 0.96)中仍无预后意义。PSM分析(n = 2715)确认生存等效性(P > 0.05)。然而,在年龄>49岁、肿瘤大小11 - 20mm的IB1期腺鳞癌/腺癌患者中,RH的DSS更佳(P = 0.01),尽管OS差异无统计学意义(P = 0.085)。无论手术方式如何,鳞状细胞癌的结果均等效(P = 0.43)。
对于大多数肿瘤≤2cm的早期宫颈癌患者,TH的生存结果与RH相当,支持其在低风险人群中的应用。然而,对于年龄>49岁、肿瘤大小11 - 20mm的IB1期腺癌或腺鳞癌患者,RH仍是首选。省略LVSI和基质深度评估的简化标准可在不影响安全性的情况下提高资源有限环境中的可及性。